Protective effects of insulin‐like growth factor‐I on the somatostatinergic system in the temporal cortex of β‐amyloid‐treated rats

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neurochemistry

• Publication date

  2005-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1471-4159.2004.02889.xPMID 15659230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MGLuR5 activation reduces β‐amyloid‐induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis‐inducing factor

  2004cited by this paper
• Comparative signaling pathways of insulin‐like growth factor‐1 and brain‐derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival

  2004cited by this paper
• Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations.

  2004cited by this paper
• Disorders of face perception and recognition.

  2003cited by this paper
• Changes in Intracellular Calcium and Glutathione in Astrocytes as the Primary Mechanism of Amyloid Neurotoxicity

  2003cited by this paper
• Amyloid‐beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation

  2003cited by this paper
• Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis.

  2002cited by this paper
• Serum insulin-like growth factor I regulates brain amyloid-β levels

  2002cited by this paper
• Is there a gender difference of somatostatin-receptor density in the human brain?

  2002cited by this paper
• In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients

  2002cited by this paper
• Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling

  2002cited by this paper
• Intracellular Amyloid-β1–42, but Not Extracellular Soluble Amyloid-β Peptides, Induces Neuronal Apoptosis*

  2002cited by this paper
• Signaling Events in Amyloid β-Peptide-induced Neuronal Death and Insulin-like Growth Factor I Protection*

  2002cited by this paper
• In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients.

  2002cited by this paper
• Serum insulin-like growth factor I regulates brain amyloid-beta levels.

  2002cited by this paper
• Different Mechanisms of Oxidative Stress and Neurotoxicity for AlzheimersA ‚(1-42) and A‚(25-35)

  2001influential reference
• Receptor-G-protein signalling in Alzheimer's disease.

  2001cited by this paper
• Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35).

  2001influential reference
• Circulating Insulin-Like Growth Factor I Mediates the Protective Effects of Physical Exercise against Brain Insults of Different Etiology and Anatomy

  2001cited by this paper
• Insulin-Like Growth Factor I (IGF-I) Protects Cells from Apoptosis by Alzheimer's V642I Mutant Amyloid Precursor Protein through IGF-I Receptor in an IGF-Binding Protein-Sensitive Manner

  2001cited by this paper
• The effect of age on the response of the rat brains to continuous beta-amyloid infusion.

  2001cited by this paper
• The effect of age on the response of the rat brains to continuous β-amyloid infusion☆

  2001influential reference
• Differences in survival‐promoting effects and intracellular signaling properties of BDNF and IGF‐1 in cultured cerebral cortical neurons

  2001cited by this paper
• Neurodegeneration is associated to changes in serum insulin-like growth factors.

  2000cited by this paper
• Circulating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain

  2000cited by this paper
• Gene structure and regulation of the somatostatin receptor type 2.

  2000cited by this paper
• Insulin‐like growth factor‐I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and Alzheimer disease brains

  2000cited by this paper
• Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.

  1999cited by this paper
• Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

  1999cited by this paper
• Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40).

  1999cited by this paper
• The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis

  1998cited by this paper
• Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia.

  1998cited by this paper
• Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: II. A study in the infant rat

  1997cited by this paper
• Somatostatin receptors.

  1997cited by this paper
• Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity.

  1997cited by this paper
• Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt

  1997influential reference
• Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I a study on ad libitum fed and starved adult male rats

  1997cited by this paper
• Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia.

  1997cited by this paper
• Impaired G-protein-stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase A activity.

  1996cited by this paper
• Dysfunction of Cholinergic and Dopaminergic Neuronal Systems in β‐Amyloid Protein‐Infused Rats

  1996cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Reversion of β25–35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists

  1996cited by this paper
• Molecular biology of somatostatin receptors.

  1995cited by this paper
• Insulin-like growth factors cross the blood-brain barrier.

  1994cited by this paper
• β-Amyloid protein-induced Alzheimer's disease animal model

  1994influential reference
• Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex.

  1994cited by this paper
• Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study.

  1993cited by this paper
• Molecular biology of somatostatin receptors.

  1993cited by this paper
• Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease.

  1991cited by this paper
• Somatostatin receptors in the senescent rat brain: a quantitative autoradiographic study.

  1991cited by this paper
• Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain.

  1991cited by this paper
• Neurotransmitter changes in alzheimer's disease: Implications to diagnostics and therapy

  1990cited by this paper
• Somatostatin inhibition of adenylate cyclase activity in different brain areas.

  1989cited by this paper
• Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory proteins.

  1986cited by this paper
• Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease.

  1985cited by this paper
• Somatostatin receptor binding in rat cerebral cortex. Characterization using a nonreducible somatostatin analog.

  1983cited by this paper
• The rat brain in stereotaxic coordinates: Authors: George Paxinos & Charles Watson Academic Press Australia, 1982 Softback, 154 pages (including 71 plates), 35.00 Aust $

  1983influential reference
• [Quantitative autoradiography].

  1982cited by this paper
• High affinity binding sites for a somatostatin-28 analog in rat brain.

  1981cited by this paper
• Ligand: a versatile computerized approach for characterization of ligand-binding systems.

  1980cited by this paper
• Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat.

  1978cited by this paper
• INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY

  1976cited by this paper
• A protein binding assay for adenosine 3':5'-cyclic monophosphate.

  1970cited by this paper
• REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐I

  1966cited by this paper
• THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

  1963cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Reduction in Hippocampal Amyloid-β Peptide (Aβ) Content during Glycine-Proline-Glutamate (Gly-Pro-Glu) Co-Administration Is Associated with Changes in Inflammation and Insulin-like Growth Factor (IGF)-I Signaling

  2024cites this paper
• Physical Exercise Counteracts Aging-Associated White Matter Demyelination Causing Cognitive Decline

  2024cites this paper
• Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting

  2024cites this paper
• Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.

  2022cites this paper
• Somatostatin Ameliorates β-Amyloid-Induced Cytotoxicity via the Regulation of CRMP2 Phosphorylation and Calcium Homeostasis in SH-SY5Y Cells

  2021cites this paper
• DAILY OSCILLATION OF COGNITIVE FACTORS IS MODIFIED IN THE TEMPORAL CORTEX OF AN AMYLOID β(1-42)-INDUCED RAT MODEL OF ALZHEIMER'S DISEASE.

  2021cites this paper
• Physical Exercise-Induced Myokines in Neurodegenerative Diseases

  2021cites this paper
• Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?

  2020cites this paper
• Improvement in inflammation is associated with the protective effect of Gly‐Pro‐Glu and cycloprolylglycine against A&bgr;‐induced depletion of the hippocampal somatostatinergic system

  2019cites this paper
• Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer’s Disease

  2019cites this paper
• The role of Insulin-like Growth Factors (IGFs) and IGF-binding proteins in the nervous system

  2019cites this paper
• The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins in the Nervous System

  2019cites this paper
• The Protective Effects of IGF-I against β-Amyloid-related Downregulation of Hippocampal Somatostatinergic System Involve Activation of Akt and Protein Kinase A.

  2018cites this paper
• An acute bout of aerobic or strength exercise specifically modifies circulating exerkine levels and neurocognitive functions in elderly individuals with mild cognitive impairment

  2017cites this paper
• Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer’s Disease

  2016cites this paper
• Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future

  2016cites this paper
• Reduction in Aβ‐induced cell death in the hippocampus of 17β‐estradiol‐treated female rats is associated with an increase in IGF‐I signaling and somatostatinergic tone

  2015cites this paper
• Aktivitätsabhängige Genregulation von Neurotrophen Faktoren und Wachstumsfaktoren am transgenen Alzheimer Mausmodell

  2014cites this paper
• Proceso inflamatorio en la enfermedad de Alzheimer. Papel de las citoquinas

  2014cites this paper
• Insulin–Leptin Signaling in the Brain

  2013cites this paper
• Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities.

  2013cites this paper
• 4 INSULIN – LEPTIN SIGNALING IN THE BRAIN

  2013cites this paper
• Somatostatin and cognitive function in neurodegenerative disorders.

  2012cites this paper
• Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer’s Disease

  2012cites this paper
• A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines

  2012cites this paper
• A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease

  2011cites this paper
• Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease

  2010cites this paper
• Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment.

  2010cites this paper
• Differential Proteomics Analysis of Specific Carbonylated Proteins in the Temporal Cortex of Aged Rats: The Deterioration of Antioxidant System

  2009cites this paper
• Minocycline prevents Abeta(25-35)-induced reduction of somatostatin and neprilysin content in rat temporal cortex.

  2009cites this paper
• Sulfadiazine Partially Protects the Rat Temporal Cortex from Amyloid Beta Peptide (25–35)-Induced Alterations of the Somatostatinergic System

  2009cites this paper
• Attenuation of AD‐like neuropathology by harnessing peripheral immune cells: local elevation of IL‐10 and MMP‐9

  2009cites this paper
• Selective apoptosis induction in the hippocampal mossy fiber pathway by exposure to CT105, the C-terminal fragment of Alzheimer's amyloid precursor protein.

  2009cites this paper
• Insulin rescues amyloid-induced impairment of hippocampal long-term potentiation

  2009cites this paper
• Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex.

  2008cites this paper
• Insulin like growth factor‐1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease

  2008cites this paper
• Somatostatin and Alzheimer's disease.

  2008cites this paper
• Role of Insulin Metabolism Disturbances in the Development of Alzheimer Disease: Mini Review

  2008cites this paper
• Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.

  2008cites this paper
• Somatostatinergic systems in brain: networks and functions.

  2008cites this paper
• 17β-Estradiol protects depletion of rat temporal cortex somatostatinergic system by β-amyloid

  2007cites this paper
• An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology.

  2007cites this paper
• Beta-amyloid toxicity and reversal in embryonic rat septal neurons.

  2007cites this paper
• POTENTIAL NON-GROWTH USES OF rhIGF-I.

  2007cites this paper
• 17Beta-estradiol protects depletion of rat temporal cortex somatostatinergic system by beta-amyloid.

  2007cites this paper
• Beta-Amyloid Toxicity in Embryonic Rat Astrocytes

  2007cites this paper
• A vitamin A-free diet results in impairment of the rat hippocampal somatostatinergic system.

  2006cites this paper
• Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

  2006cites this paper
• Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease.

  2006cites this paper
• The insulin-like growth factor system and its pleiotropic functions in brain.

  2005cites this paper